EOS med chem is the only manufacturer that provides excellent quality chemistry products and services at affordable rates. The experts working here are highly trained to handle these chemicals used in the creation of medicines used for treating various life-threatening diseases. We are into the manufacturing of chemical products after doing a deep research for the same.
EOS team of experts holds the work experience of more than ten years, and therefore we can assure you about the quality and superiority of the products and services we offer to all our valued clients around the globe. At present, this organization is listed among the most leading pharmaceutical suppliers around the world. We always supply products keeping the affordability in mind.
Welcome, 2018 CHINA CPHI, W4E82
EOS Med Chem, Medchem is Big
執大象，天下往，往而無害，安平泰
WEB: www.eosmedchem.com
EMAIL: info@eosmedchem.com; eosmedchem@gmail.com; eosmedchem@qq.com
TEL: 0086-531-69905422
GMP PLANT: No. 37, Yulong Road, Qufu City, Shandong Province.
執大象，天下往，往而無害，安平泰
WEB: www.eosmedchem.com
EMAIL: info@eosmedchem.com; eosmedchem@gmail.com; eosmedchem@qq.com
TEL: 0086-531-69905422
GMP PLANT: No. 37, Yulong Road, Qufu City, Shandong Province.
1.
Ivosidenib; AG-120 (CAS 1448347-49-6) : HPLC99.2%, LCMS, NMR, ROS, MOA, COA is ok, stock more than 10G.
Name: Ivosidenib
CAS#: 1448347-49-6 (Ivosidenib)
Chemical Formula: C28H22ClF3N6O3
Exact Mass: 582.1394
Molecular Weight: 582.97
Elemental Analysis: C, 57.69; H, 3.80; Cl, 6.08; F, 9.78; N, 14.42; O, 8.23
Related CAS #: 1448347-49-6 (Ivosidenib) 1448346-63-1 (AG-120 racemic)
Synonym: Ivosidenib, AG-120
IUPAC/Chemical Name: (S)-N-((S)-1-(2-chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-1-(4-cyanopyridin-2-yl)-N-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide
InChi Key: WIJZXSAJMHAVGX-DHLKQENFSA-N
SMILES Code: O=C([C@H](CC1)N(C2=NC=CC(C#N)=C2)C1=O)N([C@@H](C3=CC=CC=C3Cl)C(NC4CC(F)(F)C4)=O)C5=CC(F)=CN=C5
2.
Ivosidenib; AG-120 (CAS 1448347-49-6) Intermeidates:
Ivosidenib intermediate：dipropan-2-yl 3,3-dimethoxycyclobutane-1,1-dicarboxylate,
CAS# 115118-68-8, HPLC 99%, LCMS, HNMR, ROS, MOA, COA is ok, stock more than 1KG.
Ivosidenib intermediate：3-oxocyclobutane-1-carboxylic acid,
Ivosidenib intermediate：3,3-difluorocyclobutanamine hydrochloride, 
Ivosidenib intermediate：2-Chlorobenzaldehyde, 
Ivosidenib intermediate：3-AMINO-5-FLUOROPYRIDINE,
Ivosidenib intermediate：L-Pyroglutamic acid, 
Ivosidenib intermediate：3,3-DIFLUORO-CYCLOBUTANECARBONITRILE,
Ivosidenib intermediate：2-Bromo-4-cyanopyridine, 
REFERENCES
1: Birendra KC, DiNardo CD. Evidence for Clinical Differentiation and Differentiation Syndrome in Patients With Acute Myeloid Leukemia and IDH1 Mutations Treated With the Targeted Mutant IDH1 Inhibitor, AG-120. Clin Lymphoma Myeloma Leuk. 2016 Aug;16(8):460-5. doi: 10.1016/j.clml.2016.04.006. PubMed PMID: 27245312; PubMed Central PMCID: PMC4983480.
2: Brody JR, Yabar CS, Zarei M, Bender J, Matrisian LM, Rahib L, Heartwell C, Mason K, Yeo CJ, Peiper SC, Jiang W, Varieur K, Madhavan S, Petricoin E 3rd, Fortuna D, Curtis M, Wang ZX, Pishvaian MJ, Winter JM. Identification of a novel metabolic-related mutation (IDH1) in metastatic pancreatic cancer. Cancer Biol Ther. 2016 Jul 28:0. [Epub ahead of print] PubMed PMID: 27466707.
3: Caino MC, Altieri DC. Molecular Pathways: Mitochondrial Reprogramming in Tumor Progression and Therapy. Clin Cancer Res. 2016 Feb 1;22(3):540-5. doi: 10.1158/1078-0432.CCR-15-0460. Review. PubMed PMID: 26660517; PubMed Central PMCID: PMC4738153.
4: Chen J, Yang J, Cao P. The Evolving Landscape in the Development of Isocitrate Dehydrogenase Mutant Inhibitors. Mini Rev Med Chem. 2016;16(16):1344-1358. PubMed PMID: 27292784.
5: Cuyàs E, Fernández-Arroyo S, Corominas-Faja B, Rodríguez-Gallego E, Bosch-Barrera J, Martin-Castillo B, De Llorens R, Joven J, Menendez JA. Oncometabolic mutation IDH1 R132H confers a metformin-hypersensitive phenotype. Oncotarget. 2015 May 20;6(14):12279-96. PubMed PMID: 25980580; PubMed Central PMCID: PMC4494938.
6: IDH1 inhibitor shows promising early results. Cancer Discov. 2015 Jan;5(1):4. doi: 10.1158/2159-8290.CD-NB2014-178. PubMed PMID: 25583779.
7: Lippi G, Franchini M, Targher G, Poli G, Guidi GC. The significance of evaluating conventional inflammatory markers in Von Willebrand factor measurement. Clin Chim Acta. 2007 Jun;381(2):167-70. PubMed PMID: 17433810.
8: Mayer A, Schatz GC. Enhanced polarizability of aromatic molecules placed in the vicinity of silver clusters. J Phys Condens Matter. 2009 Aug 12;21(32):325301. doi: 10.1088/0953-8984/21/32/325301. PubMed PMID: 21693964.
9: Mayer A, González AL, Aikens CM, Schatz GC. A charge-dipole interaction model for the frequency-dependent polarizability of silver clusters. Nanotechnology. 2009 May 13;20(19):195204. doi: 10.1088/0957-4484/20/19/195204. PubMed PMID: 19420635.
10: Yang X, Cai W, Shao X. Structural variation of silver clusters from Ag13 to Ag160. J Phys Chem A. 2007 Jun 14;111(23):5048-56. PubMed PMID: 17516636.
Ivosidenib intermediate：3,3-difluorocyclobutanamine hydrochloride,
CAS# 637031-93-7, HPLC 99%, LCMS, HNMR, ROS, MOA, COA is ok, stock more than 1KG.
Ivosidenib intermediate：2-Chlorobenzaldehyde,
CAS# 89-98-5, HPLC 99%, LCMS, HNMR, ROS, MOA, COA is ok, stock more than 1KG.
Ivosidenib intermediate：3-AMINO-5-FLUOROPYRIDINE,
CAS# 210169-05-4, HPLC 99%, LCMS, HNMR, ROS, MOA, COA is ok, stock more than 1KG.
Ivosidenib intermediate：L-Pyroglutamic acid,
CAS# 98-79-3, HPLC 99%, LCMS, HNMR, ROS, MOA, COA is ok, stock more than 10KG.
Ivosidenib intermediate：3,3-DIFLUORO-CYCLOBUTANECARBONITRILE,
CAS# 86770-80-1, HPLC 99%, LCMS, HNMR, ROS, MOA, COA is ok, stock more than 10KG.
Ivosidenib intermediate：2-Bromo-4-cyanopyridine,
CAS# 10386-27-3, HPLC 99%, LCMS, HNMR, ROS, MOA, COA is ok, stock more than 10KG.
REFERENCES
1: Birendra KC, DiNardo CD. Evidence for Clinical Differentiation and Differentiation Syndrome in Patients With Acute Myeloid Leukemia and IDH1 Mutations Treated With the Targeted Mutant IDH1 Inhibitor, AG-120. Clin Lymphoma Myeloma Leuk. 2016 Aug;16(8):460-5. doi: 10.1016/j.clml.2016.04.006. PubMed PMID: 27245312; PubMed Central PMCID: PMC4983480.
2: Brody JR, Yabar CS, Zarei M, Bender J, Matrisian LM, Rahib L, Heartwell C, Mason K, Yeo CJ, Peiper SC, Jiang W, Varieur K, Madhavan S, Petricoin E 3rd, Fortuna D, Curtis M, Wang ZX, Pishvaian MJ, Winter JM. Identification of a novel metabolic-related mutation (IDH1) in metastatic pancreatic cancer. Cancer Biol Ther. 2016 Jul 28:0. [Epub ahead of print] PubMed PMID: 27466707.
3: Caino MC, Altieri DC. Molecular Pathways: Mitochondrial Reprogramming in Tumor Progression and Therapy. Clin Cancer Res. 2016 Feb 1;22(3):540-5. doi: 10.1158/1078-0432.CCR-15-0460. Review. PubMed PMID: 26660517; PubMed Central PMCID: PMC4738153.
4: Chen J, Yang J, Cao P. The Evolving Landscape in the Development of Isocitrate Dehydrogenase Mutant Inhibitors. Mini Rev Med Chem. 2016;16(16):1344-1358. PubMed PMID: 27292784.
5: Cuyàs E, Fernández-Arroyo S, Corominas-Faja B, Rodríguez-Gallego E, Bosch-Barrera J, Martin-Castillo B, De Llorens R, Joven J, Menendez JA. Oncometabolic mutation IDH1 R132H confers a metformin-hypersensitive phenotype. Oncotarget. 2015 May 20;6(14):12279-96. PubMed PMID: 25980580; PubMed Central PMCID: PMC4494938.
6: IDH1 inhibitor shows promising early results. Cancer Discov. 2015 Jan;5(1):4. doi: 10.1158/2159-8290.CD-NB2014-178. PubMed PMID: 25583779.
7: Lippi G, Franchini M, Targher G, Poli G, Guidi GC. The significance of evaluating conventional inflammatory markers in Von Willebrand factor measurement. Clin Chim Acta. 2007 Jun;381(2):167-70. PubMed PMID: 17433810.
8: Mayer A, Schatz GC. Enhanced polarizability of aromatic molecules placed in the vicinity of silver clusters. J Phys Condens Matter. 2009 Aug 12;21(32):325301. doi: 10.1088/0953-8984/21/32/325301. PubMed PMID: 21693964.
9: Mayer A, González AL, Aikens CM, Schatz GC. A charge-dipole interaction model for the frequency-dependent polarizability of silver clusters. Nanotechnology. 2009 May 13;20(19):195204. doi: 10.1088/0957-4484/20/19/195204. PubMed PMID: 19420635.
10: Yang X, Cai W, Shao X. Structural variation of silver clusters from Ag13 to Ag160. J Phys Chem A. 2007 Jun 14;111(23):5048-56. PubMed PMID: 17516636.
